Selvita S.A. (WSE:SLV)

Market Cap	357.93M -46.0%
Revenue (ttm)	349.00M -6.7%
Net Income	-2.08M
EPS	-0.12
Shares Out	18.36M
PE Ratio	n/a
Forward PE	91.62
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,731
Open	19.84
Previous Close	20.00
Day's Range	19.30 - 19.88
52-Week Range	19.34 - 49.40
Beta	0.10
Analysts	Hold
Price Target	35.85 (+83.85%)
Earnings Date	Sep 17, 2026

About Selvita

Selvita S.A. provides drug discovery, drug development, and contract testing services in Poland. The company offers computer-aided drug design and artificial intelligence solutions, including structure-based drug design, virtual screening, and bioinformatics; medicinal and synthetic, analytical, and solid state chemistry, as well as process chemistry and scale up, and compound management and libraries; structural biology, fragment-based drug discovery, protein production, modification, and characterization; vitro assays and model, mechanistic a...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2007
• Employees: 899
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: SLV

Analyst Summary

According to 6 analysts, the average rating for SLV stock is "Hold." The 12-month stock price target is zł 35.85, which is an increase of 83.85% from the latest price.

Price Target

zł 35.85

(83.85% upside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 15, 2026

Data Sources Report a data error